|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | BCLC策略:预后预测和治疗推荐2022版更新显示文摘2018版BCLC预后和治疗推荐策略发布后,肝细胞癌(简称HCC)的研究又取得了重大进展。本次更新基于肝癌各领域的研究进展结果。重点关注影响策略的重要研究进展。虽然近年的研究结果成绩斐然,但将其引入为临床医生和研究者提供行动依据的循证模型指南来说证据效力依然不够确切。本文对该问题进行分析,阐述了为HCC患者制定个体化治疗临床决策所需的批判性思维和专业知识。 | Reig M Forner A Rimola J Ferrer-Fabrega J Burrel M Garcia-Criado A Kelley RK Galle PR Mazzaferro V Salem R Sangro B Singal AG Vogel A Fuster J Ayuso C Bruix J 刘永凡(摘译) 崔笑(摘译) 耿小平(审校) | 2022 | 肝胆外科杂志2022，30，5： | 80 |
| 2 | 在没有危险因素的情况下,正常的低密度脂蛋白胆固醇水平与亚临床动脉粥样硬化相关显示文摘普遍认为缺乏心血管病危险因素(cardiovascular risk factors,CVRF)人群的动脉粥样硬化发生风险低,然而,无CVRF的个体仍然有心血管事件发生。为了确定无CVRF个体中亚临床动脉粥样硬化的预测因子, | Fernández-Friera L Fuster V López-Melgar B Oliva B García-Ruiz JM Mendiguren J Bueno H Pocock S Ibánez B Fernández-Ortiz A Sanz J 刘莉 叶鹏 | 2017 | 中华高血压杂志2017，25，12： | 17 |
| 3 | Management of nonalcoholic fatty liver disease:An evidence-based clinical practice review显示文摘AIM:To build a consensus among Chilean specialists on the appropriate management of patients with nonalcoholic fatty liver disease(NAFLD)in clinical practice.METHODS:NAFLD has now reached epidemic proportions worldwide.The optimal treatment for NAFLD has not been established due to a lack of evidence-based recommendations.An expert panel of members of the Chilean Gastroenterological Society and the Chilean Hepatology Association conducted a structured analysis of the current literature on NAFLD therapy.The quality of the evidence and the level of recommendations supporting each statement were assessed according to the recommendations of the United States Preventive Services Task Force.A modified three-round Delphi technique was used to reach a consensus among the experts.RESULTS:A group of thirteen experts was established.The survey included 17 open-ended questions that were distributed among the experts,who assessed the articles associated with each question.The levels of agreement achieved by the panel were 93.8%in the first round and 100%in the second and third rounds.The final recommendations support the indication of lifestyle changes,including diet and exercise,for all patients with NAFLD.Proven pharmacological therapies include only vitamin E and pioglitazone,which can be used in nondiabetic patients with biopsy-proven nonalcoholic steatohepatitis(the progressive form of NAFLD),although the long-term safety and efficacy of these therapies have not yet been established.CONCLUSION:Current NAFLD management is rapidly evolving,and new pathophysiology-based therapies are expected to be introduced in the near future.All NAFLD patients should be evaluated using a three-focused approach that considers the risks of liver disease,diabetes and cardiovascular events. | Juan P Arab Roberto Candia Rodrigo Zapata Cristián Mu?oz Juan P Arancibia Jaime Poniachik Alejandro Soza Francisco Fuster Javier Brahm Edgar Sanhueza Jorge Contreras M Carolina Cuellar Marco Arrese Arnoldo Riquelme | 2014 | World Journal of Gastroenterology2014，20，34： | 11 |
| 4 | Expansion of the hepatocellular carcinoma Milan criteria in liver transplantation: Future directions显示文摘Milan criteria are currently the benchmark related to liver transplantation(LT) for hepatocellular carcinoma. However, several groups have proposed different expanded criteria with acceptable results. In this article, we review the current status of LT beyond the Milan criteria in three different scenarios-expanded criteria with cadaveric LT, downstaging to Milan criteria before LT, and expansion in the context of adult living donor LT. The review focuses on three main questions: what would the impact of the expansion beyond Milan criteria be on the patients on the waiting list; whether the dichotomous criteria(yes/no) currently used are appropriate for LT or continuous survival estimations, such as the one of 'Metroticket' and whether it should enter into the clinical practice; and, whether the use of living donor LT in the context of expansion beyond Milan criteria is justified. | Mihai-Calin Pavel Josep Fuster | 2018 | World Journal of Gastroenterology2018，24，32： | 10 |
| 5 | Prognostic factors and time-related changes influence results of colorectal liver metastases surgical treatment:A single-center analysis显示文摘AIM:To analyze the prognostic factors involved in survival and cancer recurrence in patients undergoing surgical treatment for colorectal liver metastases(CLM) and to describe the effects of time-related changes on survival and recurrence in these patients.METHODS:From January 1994 to January 2006,236 patients with CLM underwent surgery with the aim of performing curative resection of neoplastic disease at our institution and 189(80%) of these patients underwent resection of CLM with curative intention.Preoperative,intraoperative and postoperative data,including primary tumor and CLM pathology results,were retrospectively reviewed.Patients were divided into two time periods:a first period from January 1994 to January 2000(n = 93),and a second period from February 2000 to January 2006(n = 143).RESULTS:Global survival at 1,3 and 5 years in patients undergoing hepatic resection was 91%,54% and 47%,respectively.Patients with preoperative extrahepatic disease,carcinoembryonic antigen(CEA) levels over 20 ng/dL,more than four nodules or extrahepatic invasion at pathological analysis had worse survival.Tumor recurrence rate at 1 year was 48.3%,being more frequent in patients with preoperative and pathological extrahepatic disease and CEA levels over 20 ng/dL.Although patients in the second time period had more adverse prognostic factors,no differences in overall survival and recurrence were observed between the two periods.CONCLUSION:Despite advances in surgical technique and better adjuvant treatments and preoperative imaging,careful patient staging and selection is crucial to continue offering a chance of cure to patients with CLM. | Josep Martí María Marta Modolo Josep Fuster Jaume Comas Rebeca Cosa Joana Ferrer Victor Molina Juan Romero Constantino Fondevila Ramón Charco Juan Carlos García-Valdecasas | 2009 | World Journal of Gastroenterology2009，15，21： | 9 |
| 6 | Alcohol use disorder and its impact on chronic hepatitis C virus and human immunodeficiency virus infections显示文摘Alcohol use disorder(AUD) and hepatitis C virus(HCV) infection frequently co-occur. AUD is associated with greater exposure to HCV infection, increased HCV infection persistence, and more extensive liver damage due to interactions between AUD and HCV on immune responses, cytotoxicity, and oxidative stress. Although AUD and HCV infection are associated with increased morbidity and mortality, HCV antiviral therapy is less commonly prescribed in individuals with both conditions. AUD is also common in human immunodeficiency virus(HIV) infection, which negatively impacts proper HIV care and adherence to antiretroviral therapy, and liver disease. In addition, AUD and HCV infection are also frequent within a proportion of patients with HIV infection, which negatively impacts liver disease. This review summarizes the current knowledge regarding pathological interactions of AUD with hepatitis C infection, HIV infection, and HCV/HIV co-infection, as well as relating to AUD treatment interventions in these individuals. | Daniel Fuster Arantza Sanvisens Ferran Bolao Inmaculada Rivas Jordi Tor Robert Muga | 2016 | World Journal of Hepatology2016，8，31： | 4 |
| 7 | Cholesterol Efflux and Atheroprotection: Advancing the Concept of Reverse Cholesterol Transport显示文摘 | Robert S. Rosenson H. Bryan Brewer W. Sean Davidson Zahi A. Fayad Valentin Fuster James Goldstein Marc Hellerstein Xian-Cheng Jiang Michael C. Phillips Daniel J. Rader Alan T. Remaley George H. Rothblat Alan R. Tall Laurent Yvan-Charvet | 2012 | Circulation2012，，15： | 4 |
| 8 | Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure显示文摘 | J Bruix A Castells J Bosch F Feu J Fuster JC Garcia-Pagan J Visa C Bru J Rodes | 1996 | Gastroenterology1996，，4： | 3 |
| 9 | Management of Patients With Atrial Fibrillation: A Statement for Healthcare Professionals From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association显示文摘 | Eric N. Prystowsky Jr Benson Valentin Fuster Robert G. Hart G. Neal Kay Robert J. Myerburg Gerald V. Naccarelli D. George Wyse | 1996 | Circulation1996，，6： | 2 |
| 10 | The pathogenesis of coronary artery disease and the acute coronary syndromes显示文摘 | Fuster V Badimon L Badimon JJ | 1992 | N Engl J Med1992，326，4： | 2 |
| 11 | Decompression of the Portal Bed and Twice-Baseline Portal Inflow Are Necessary for the Functional Recovery of a “Small-for-Size” Graft显示文摘 | Amelia J. Hessheimer Constantino Fondevila Pilar Taurá Javier Mu?oz Olga Sánchez José Fuster Antoni Rimola Juan Carlos García-Valdecasas | 2011 | Annals of Surgery2011，，6： | 2 |
| 12 | Portal Vein Thrombosis in Liver Transplantation显示文摘 | R. Charco J. Fuster C. Fondevila J. Ferrer E. Mans J.C. Garc??a-Valdecasas | 2005 | Transplantation Proceedings2005，，9： | 2 |
| 13 | Acute Coronary Events显示文摘 | Armin Arbab-Zadeh Masataka Nakano Renu Virmani Valentin Fuster | 2012 | Circulation2012，，9： | 2 |
| 14 | Changes in Plaque Lipid Content after Short-Term, Intensive versus Standard Statin Therapy: The YELLOW Trial显示文摘 | Annapoorna S. Kini Usman Baber Jason C. Kovacic Atul Limaye Ziad A. Ali Joseph Sweeny Akiko Maehara Roxana Mehran George Dangas Gary S. Mintz Valentin Fuster Jagat Narula Samin K. Sharma Pedro R. Moreno | 2013 | Journal of the American College of Cardiology2013，，： | 2 |
| 15 | ACC/AHA/ESC更新心房颤动治疗指南显示文摘 | Fuster V Rydén LE Cannom DS 蒋晖(摘译) 蔡琳(校) | 2006 | 心血管病学进展2006，27，6： | 2 |
| 16 | The Serine Proteases and Their Function in Neuronal Death Processes显示文摘 | Fuster LO Galindo MF Cena V | 2004 | Rev Neurol(S0210--0010)2004，38，5： | 1 |
| 17 | High risk of thromboemboli early after bioprosthetic cardiac valve replacement显示文摘 | Heras M Chesebro JH Fuster V | 1995 | Am Coll Cardiol1995，25，： | 1 |
| 18 | Molecular imaging for the diagnosis of high-risk plaque显示文摘 | SIROL M FUSTER V TOUSSAINT JF | 2003 | Arch Mal Coeur Vaiss2003，96，12： | 1 |
| 19 | Management of patie nts with atrial fibrillation显示文摘 | Benson DW Fuster V | 1996 | Circulation1996，93，6： | 1 |
| 20 | The pathogenesis of coronary artery disease and the acute coronary syndromes显示文摘 | Fuster V Badimon L Badimon JJ | 1992 | N Engl J Med1992，326，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员